trans-3-(4-bromothiophen-2-yl)-acryloyl azide | 799293-81-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: trans-3-(4-bromothiophen-2-yl)-acryloyl azide
• 英文别名: (2E)-3-(4-bromo-2-thienyl)-2-propenoic acid；(E)-3-(4-bromothiophen-2-yl)acryloyl azide；(E)-3-(4-bromo-thiophen-2-yl)-acryloyl azide；3-(4-bromo-thiophene-2-yl)-acryloyl azide；(E)-3-(4-bromothiophen-2-yl)prop-2-enoyl azide
• CAS: 799293-81-5
• 化学式: C₇H₄BrN₃OS
• 分子量: 258.098
• InChiKey: IIQQGKUMZGJJOZ-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  trans-3-(4-bromothiophen-2-yl)-acryloyl azide 在 碘 、 三氯氧磷 作用下， 以 邻二氯苯 、 甲苯 为溶剂， 生成 3-溴-4-氯噻吩并[3,2-c]吡啶
  参考文献：
  名称：

  Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases

  摘要：

  A novel class of 3,7-diphenyl-4-amino-thieno and furo[3,2-c]pyridine has been designed based on pharmacophore models of ATP competitive kinase inhibitors. Versatile synthetic methods via double Suzuki coupling to explore SAR have been established and potent inhibitors against angiogenetic targets, VEGFR2, Tie-2, and EphB4, have been successfully discovered. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.050
• 作为产物：
  描述：

  (2E)-3-(4-溴-2-噻吩基)丙烯酸 在 三正丁胺 、 叠氮磷酸二苯酯 作用下， 生成 trans-3-(4-bromothiophen-2-yl)-acryloyl azide
  参考文献：
  名称：

  3-溴代噻吩并[3,2-c]吡啶-4-（5H）-one的热合成：三丁胺的伸缩方法

  摘要：

  3-溴代噻吩并[3,2- c ]吡啶-4-（5 H）-一（1）由（2 E）-3-（4-溴-2-噻吩基）-2-丙酸（3）制备由Eloy–Deryckere热苯并/杂吡啶并酮合成。开发了一种望远镜程序，可以减少与经典程序相关的一些风险。结果表明，在该过程中使用三丁胺作为添加剂可促进中间体异氰酸乙烯基酯的E / Z异构化，并降低整个热处理过程所需的温度。

  DOI：

  10.1002/jhet.1981

文献信息

• Thienopyridine and furopyridine kinase inhibitors
  申请人：Betschmann Patrick

  公开号：US20050043347A1

  公开（公告）日：2005-02-24

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US20130116233A1

  公开（公告）日：2013-05-09

  The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及一种新型化合物，其化学式为I，它们是磷酸二酯酶10A的抑制剂，并且用于制备药物，因此适用于治疗或控制从神经系统疾病和精神疾病中选择的医学疾病，改善与这些疾病相关的症状，并减少这些疾病的风险。
• Compounds
  申请人：Ford John

  公开号：US20070161672A1

  公开（公告）日：2007-07-12

  Thienopyridine compounds which are potassium channel inhibitors are described. Pharmaceutical compositions comprising the compounds and their use in the treatment or prevention of cancer, arrhythmias, autoimmune diseases and inflammatory diseases, including gastric cancer, atrial fibrillation, type-2 diabetes mellitus, rheumatoid arthritis, type-1 diabetes, inflammatory bowel disorder and demyelinating disorders such as multiple sclerosis are also disclosed.

  描述了一种钾通道抑制剂的噻吡啶类化合物。还披露了包括这些化合物的药物组合物以及它们在治疗或预防癌症、心律失常、自身免疫疾病和炎症性疾病中的用途，包括胃癌、心房颤动、2型糖尿病、类风湿性关节炎、1型糖尿病、炎症性肠道疾病和多发性硬化等脱髓鞘疾病。
• Novel chemical compounds
  申请人：Miyazaki Yasushi

  公开号：US20080182868A1

  公开（公告）日：2008-07-31

  This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

  本发明涉及治疗和预防肿瘤和癌症的新型化合物，以及用于治疗与参与增殖性疾病的酪氨酸激酶失衡或不适当活性相关的增殖性疾病的方法。
• Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A
  申请人：Abbott GmbH & Co. KG

  公开号：US09273068B2

  公开（公告）日：2016-03-01

  The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式（I）的新化合物，其中Het，A，Q，X1，X2，X3，R1和R2在规范中有定义，它们是磷酸二酯酶10A的抑制剂，并且用于制造药物，因此适用于治疗或控制选择的医学疾病，包括神经系统疾病和精神障碍，改善与此类疾病相关的症状，并降低此类疾病的风险。